

## Company Overview

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne's portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment.

Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne's genomic tools include advanced tissue-based *in situ* hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx® Prostate test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment.

Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately \$739 million in net sales in fiscal 2020 and has over 2,300 employees worldwide.

## Bio-Techne and QIAGEN Announce Expansion and Extension of Exosome Partnership

Sep 17 2020, 7:00 AM EDT

### Stock Overview

|            |                                |
|------------|--------------------------------|
| Symbol     | TECH                           |
| Exchange   | Nasdaq                         |
| Market Cap | 9.4b                           |
| Last Price | \$243.90                       |
| 52-Week    | \$155.169998 -<br>\$286.679992 |

09/18/2020 04:00 PM EDT

### Investor Relations

David Clair  
T: 612-656-4416  
[ir@bio-techne.com](mailto:ir@bio-techne.com)

## Management Team

### Charles (Chuck) Kummeth

President and Chief Executive Officer

### Jim Hippel

Chief Financial Officer

### David Eansor

President, Protein Sciences Segment

### Kim Kelderman

President, Diagnostics and Genomics

### Brenda Furlow

General Counsel, Secretary and Chief Compliance Officer

### Peter Breloer

Vice President - APAC

### Mike Deines

Vice President - Reagent Solutions Division

### Bob Gavin

Sr. Vice President - Analytical Solutions Division

### Kevin Gould

Sr. Vice President - Diagnostics Reagents Division

### Struan Robertson

Vice President - Human Resources

### Steven Silverman

Vice President - Exosome Diagnostics

### Kevin Smyth

Chief Digital Officer

### Gary Stapleton

Vice President - EMEA

### Kamni Vijay

Vice President - Genomics

## Bio-Techne Corporation

614 McKinley Place NE  
Minneapolis, MN 55413

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

